Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | SCN4A | P35499 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13984211 | 0.85 | ALOX15 (0.53) | KDM4ECYP1A2ALOX15LMNATDP1 | |
| SCHEMBL29678765 | 0.83 | CYP1A2 (0.38) | KDM4ECYP1A2SCN4AALOX15KMT2A | |
| SCHEMBL18305182 | 0.83 | CYP1A2 (0.38) | KDM4ECYP1A2SCN4AALOX15KMT2A | |
| SCHEMBL24947656 | 0.83 | CYP1A2 (0.38) | KDM4ECYP1A2SCN4AALOX15KMT2A | |
| SCHEMBL1919969 | 0.81 | LMNA (0.54) | KDM4ECYP1A2ALOX15LMNASMN1; SMN2 | |
| SCHEMBL14404028 | 0.80 | ALOX15 (0.38) | KDM4ECYP1A2SCN4AALOX15LMNA | |
| SCHEMBL31357858 | 0.80 | ALOX15 (0.38) | KDM4ECYP1A2SCN4AALOX15LMNA | |
| SCHEMBL9338341 | 0.80 | L3MBTL1 (0.56) | KDM4ECYP1A2ALOX15KMT2AMEN1 | |
| SCHEMBL22069687 | 0.80 | L3MBTL1 (0.47) | CYP1A2KMT2AMEN1SMN1; SMN2TDP1 | |
| SCHEMBL1866136 | 0.80 | KMT2A (0.48) | CYP1A2ALOX15KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3666769-A1 | NOVEL CASPASE INHIBITORS | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2020-06-17 | — | — | EP | disclosed |
| US-9802927-B2 | Oxadiazine compounds and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802927-B2 | Oxadiazine compounds and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802927-B2 | Oxadiazine compounds and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170066753-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS, INC. | 2017-03-09 | — | — | US | disclosed |
| US-20170066753-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS, INC. | 2017-03-09 | — | — | US | disclosed |
| US-20170066753-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS, INC. | 2017-03-09 | — | — | US | disclosed |
| WO-2016201168-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | FORUM PHARMCEUTICALS INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| WO-2016201168-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | FORUM PHARMCEUTICALS INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| EP-2138489-A1 | NOVEL PYRIMIDINE COMPOUND HAVING BENZYL(HETEROCYCLICMETHYL)AMINE STRUCTURE AND PHARMACEUTICAL PRODUCT CONTAINING THE SAME | Kowa Company. Ltd. (JP) | 2009-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066753-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | PSEN2, SMN1; SMN2, OTC | KDM4E 3178/4885CYP1A2 849/4885SCN4A 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.